The side effects appear consistent with the incretin class (GI issues), but as physicians, managing patient titration and comfort will be critical if this comes to market
Around 21.8% of people using salbutamol are living with obesity, with higher rates in mild to moderate cases
J Cataract Refract Surg 27(12):19691974 Alfaro DV, Liggett PE (1994) Intravenous cefazolin in penetrating eye injuries
Informed consent isnt just a formality
These changes typically emerge within the first two to three months of treatment as weight loss accelerates, and they often stabilize once your body reaches a new equilibrium weight
GLP-1 Weight Loss Drugs: The Untold Story Risks, Rebound, and the Role of Nutritional Therapy The rise in popularity of GLP-1 agonist weight loss drugs like Mounjaro (tirzepatide) and Ozempic (semaglutide) is undeniable